BeOne Medicines Ltd. (NASDAQ: BEIGF)

BeOne Medicines Ltd. is a global oncology company that discovers and develops innovative cancer treatments for patients worldwide. The company focuses on hematology and solid tumor indications building a portfolio of wholly owned and in licensed products. Its pipeline includes novel small molecules antibody drug conjugates and bispecific therapies aimed at addressing unmet medical needs.

BeOne Medicines Ltd. generates revenue primarily from sales of its approved medicines BRUKINSA and TEVIMBRA as well as from in licensed products such as XGEVA BLINCYTO and KYPROLIS that it commercializes in China. In 2025 the company reported total global revenue of approximately five point three billion dollars with BRUKINSA contributing about three point nine billion dollars. Additional revenue streams include royalties and collaboration payments from partnered development programs.

BeOne Medicines Ltd. holds a leading position in the BTK inhibitor market with BRUKINSA being the only BTK inhibitor to demonstrate superior efficacy over ibrutinib in chronic lymphocytic leukemia patients. The company is the sole entity with potentially best in class assets across three key mechanisms of action in CLL namely a BTK inhibitor a BCL2 inhibitor and a BTK degrader. Its main competitors include AbbVie Janssen AstraZeneca Eli Lilly and other major biopharmaceutical firms that market products such as IMBRUVICA CALQUENCE and JAYPIRCA.

The company serves hospitals oncology clinics and health systems that treat patients with hematologic and solid tumor cancers. Its products are reimbursed by government health programs and private insurers in markets such as the United States Europe China and Japan. BeOne Medicines Ltd. also works with distributors and specialty pharmacies to ensure broad patient access to its therapies.